Benefits of Trikafta sustained more than 3.5 years in extension trial
Long-term treatment with Trikafta leads to sustained improvements in lung function, easing of respiratory symptoms, and better nutritional status for people with cystic fibrosis (CF) who have at least one copy of the F508del mutation. That’s according to new data presented by the therapy’s developer Vertex Pharmaceuticals…